Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy.
Translational Cardiomyology Laboratory, Stem Cell Biology and Embryology, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Diabetes. 2022 May 1;71(5):1081-1098. doi: 10.2337/db21-0536.
Diabetes mellitus (DM) affects the biology of multipotent cardiac stem/progenitor cells (CSCs) and adult myocardial regeneration. We assessed the hypothesis that senescence and senescence-associated secretory phenotype (SASP) are main mechanisms of cardiac degenerative defect in DM. Accordingly, we tested whether ablation of senescent CSCs would rescue the cardiac regenerative/reparative defect imposed by DM. We obtained cardiac tissue from nonaged (50- to 64-year-old) patients with type 2 diabetes mellitus (T2DM) and without DM (NDM) and postinfarct cardiomyopathy undergoing cardiac surgery. A higher reactive oxygen species production in T2DM was associated with an increased number of senescent/dysfunctional T2DM-human CSCs (hCSCs) with reduced proliferation, clonogenesis/spherogenesis, and myogenic differentiation versus NDM-hCSCs in vitro. T2DM-hCSCs showed a defined pathologic SASP. A combination of two senolytics, dasatinib (D) and quercetin (Q), cleared senescent T2DM-hCSCs in vitro, restoring their expansion and myogenic differentiation capacities. In a T2DM model in young mice, diabetic status per se (independently of ischemia and age) caused CSC senescence coupled with myocardial pathologic remodeling and cardiac dysfunction. D + Q treatment efficiently eliminated senescent cells, rescuing CSC function, which resulted in functional myocardial repair/regeneration, improving cardiac function in murine DM. In conclusion, DM hampers CSC biology, inhibiting CSCs' regenerative potential through the induction of cellular senescence and SASP independently from aging. Senolytics clear senescence, abrogating the SASP and restoring a fully proliferative/differentiation-competent hCSC pool in T2DM with normalization of cardiac function.
糖尿病(DM)影响多能心脏干细胞/祖细胞(CSC)和成人心肌再生的生物学特性。我们假设衰老和衰老相关分泌表型(SASP)是 DM 中心脏退行性病变的主要机制,并测试了是否消除衰老的 CSC 可以挽救 DM 引起的心脏再生/修复缺陷。我们从接受心脏手术的患有 2 型糖尿病(T2DM)和无 DM(NDM)的非老年(50-64 岁)患者以及心肌梗死后的心脏组织中获得心脏组织。T2DM 中活性氧的产生增加与衰老/功能障碍的 T2DM 人 CSC(hCSC)数量增加有关,与 NDM-hCSC 相比,T2DM-hCSC 的增殖、克隆形成/球体形成和肌源性分化减少。T2DM-hCSC 表现出明确的病理性 SASP。两种衰老抑制剂(达沙替尼(D)和槲皮素(Q)的组合)可在体外清除衰老的 T2DM-hCSC,恢复其扩增和肌源性分化能力。在年轻小鼠的 T2DM 模型中,糖尿病状态本身(独立于缺血和年龄)导致 CSC 衰老,伴有心肌病理性重塑和心功能障碍。D + Q 治疗可有效消除衰老细胞,恢复 CSC 功能,从而实现功能性心肌修复/再生,改善小鼠 DM 的心脏功能。总之,DM 会损害 CSC 生物学,通过诱导细胞衰老和 SASP 抑制 CSC 的再生潜能,与衰老无关。衰老抑制剂可清除衰老细胞,消除 SASP 并恢复 T2DM 中具有完全增殖/分化能力的 hCSC 池,从而使心脏功能正常化。